Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• European American patients with deoxyribonucleic acid (DNA) available and designated case or control
• Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab
• Patients who did not develop hypertension following a full course of treatment with bevacizumab
Locations
United States
Massachusetts
Eastern Cooperative Oncology Group
RECRUITING
Boston
Time Frame
Start Date: 2014-03-25
Estimated Completion Date: 2100-01-01
Participants
Target number of participants: 354
Treatments
Ancillary-Correlative (whole exome sequencing)
Previously collected germline DNA samples are analyzed via whole exome sequencing.
Authors
Related Therapeutic Areas
Sponsors
Leads: National Cancer Institute (NCI)